Karen Reckamp, MD, MS retweeted
Finishing the 2026 Consensus Conference in Early #lungcancer thanks to @peters_solange @FedericoCappuz1 for organizing the event, more than 60 experts attended from the five continents.
@JuliaRotow @ReckampK @delvysra @EddieSantosMD @ogarrieta @BairdAM @Piuchagarrido @BrendonStilesMD @LudaBazhenovaMD @HHorinouchi @t_mitsudomi
Karen Reckamp, MD, MS retweeted
#MaTOSLung25 @NaglaAKarimMD @GWtweets presents a challenging case of locally advanced #atypicalcarcinoid - when is adjuvant chemotherapy indicated?
Karen Reckamp, MD, MS retweeted
Great debate on “Is perioperative chemoimmunotherapy the new SOC?” Both the “yes” (@Joshua_Reuss) and “no” (@BalazsHalmosMD) delivered strong arguments with humors.
A very close call, but Dr. Reuss took home the win 🏆.
#MaTOS25
Karen Reckamp, MD, MS retweeted
Dr. @chulkimMD leads a dynamic case discussion of PD-L1 negative squamous NSCLC at #MaTOSLung.
Karen Reckamp, MD, MS retweeted
The #MaTOS Lung conference is a unique fun and practical forum for us to discuss real clinical cases and learn from each other. Thank you Chairs @EddieSantosMD @LuisRaezMD @ReckampK @christine_lovly
Discussing the latest data and challenging cases at #MaTOSLung to answer the questions of tomorrow with colleagues and friends, new and old. Thanks to all for your efforts for a successful forum. #LCSM
2
2
154
Karen Reckamp, MD, MS retweeted
#MaTOSLung @BiagioRicciutMD @DanaFarber presents one of the most challenging #lungcancer cases Stage IV KRASG12D STK11 PDL1 high w rapid progression
👉🏽highlighting the big area of need to find treatments for patients who have poor IO prognostic indicators
Karen Reckamp, MD, MS retweeted
Our Faculty
#MaTOSLung2025 #OncologyEducation #LungCancerCare
@EddieSantosMD @LuisRaezMD @KarenReckampMD @NaglaAKarimMD @LauraAlderMD
@LudaBazhenovaMD
@JeffBradleyMD
@DCarboneMD
@yyelamin
@maryjofidlermd
@drgandara
@BalazsHalmosMD
@WadeIams
@iyengarpuneeth
@karenkellymd
@chulkimMD
@lexiuning
@JessicaJLinMD @StephenVLiu @Christine_Lovly
@LindaMThoracic
@MNagasaka
@luisraezMD
@Joshua_Reuss @BiagioRicciutMD
@latinamd
@delvysra
@EddieSantosMD
@drshieldsmd
@lungoncdoc
@FSkoulidis @AnaVManana @maraantonoff
Karen Reckamp, MD, MS retweeted
What a great start Day 3 of MaTOS Lung with small cell lung cancer. Drs. Misty Shields, Punneth Iyengar and Christine Hann. Dr Hann from John Hopkins presenting the novel agents which are coming: ATR, EZH, VEGF, ADC and TcE. The group led by Professor Paul Bunn. @OncologyInst @LuisRaezMD @christine_lovly @ReckampK @FLASCO_ORG @IASLC @ASCO @mecmededucation @faucollegeofmed @Latinamd @lungoncdoc @drgandara @danmorg1970 @IyengarPuneeth @drshieldsmd – at Tortolita, AZ
Karen Reckamp, MD, MS retweeted
Congratulations to the 2025 @IASLC, distinguished service award winners! Grateful for all the impact and happiness is the recognition at #WCLC25 for Drs. Sanja Dacic, Pasi Janne, @peters_solange and Wytold Rzyman!
Join us for the Year in Review Live Webinar | Targeted Therapy for Non-Small Cell Lung Cancer Edition on May 8, 4:30-6pm ET. Dr. Justin Gainor and I will discuss the latest updates with Dr. Neil Love to improve patient care and outcomes. #LCSM
m.researchtopractice.com/Web…
#AACR24 @BhowmickNeil and Manish Thiruvalluvan present exciting work on persister cells in EGFR NSCLC @CSCancerCenter
Karen Reckamp, MD, MS retweeted
Karen Reckamp, MD, MS retweeted
The @LungMAP trial has new leadership! @HosseinBorghaei of @FoxChaseCancer & @eaonc is new chair of the Lung-MAP master protocol. @ReckampK of @CedarsSinai & @SWOG is vice chair. @DrRoyHerbstYale & @JPatelMD are outgoing chair & vice chair @NCICTEP_ClinRes @CancerResrch @FNIH_Org
Congratulations to the @LungMAP team for 10 years of dedication and success. Teamwork and commitment to patients is the key. Excellent talk by @DrRoyHerbstYale at SWOG. It takes a village. @drgandara @JPatelMD Mary Redman, Vali Papadimitrakopoulou and so many others. #SWOG #LCSM
It’s been refreshing to see colleagues and discuss the data at #ASCO2022 We are excited to see coverage #ASCODailyNews of the OS benefit for previously treated NSCLC with ramucirumab and pembrolizumab in S1800A @ASCO dailynews.ascopubs.org/do/10…












































